Clovis up on supply deal for component related to cancer therapy

Clovis Oncology

21/09/2022 17:03

** Shares of Clovis Oncology Inc  CLVS.O  rise 5.3% to $1.18
    ** Co signs agreement with Isotopia Molecular Imaging Ltd
for supplying medical radioisotope, lutetium-177, for
development of its cancer therapy candidate FAP-2286
 urn:newsml:reuters.com:*:nBw3z4BJja
    ** Deal covers an initial period of two years; further
details have not been disclosed
    ** Co's therapy candidate will contain two parts – a peptide
molecule that attaches to a target on a potential cancer cell,
and the radioactive chemical lutetium-177 targeting the tumor
    ** Including session's gain, stock down ~56% YTD

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))